Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

@article{Drilon2017SafetyAA,
  title={Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).},
  author={Alexander E Drilon and Salvatore Siena and S H Ignatius Ou and Manish R Patel and Myung Ju Ahn and Jeeyun Lee and Todd M. Bauer and Anna F. Farago and Jennifer J. Wheler and Stephen V Liu and Robert C Doebele and Laura Giannetta and Giulio Cerea and Giovanna Marrapese and Michele Schirru and Alessio Amatu and Katia Bruna Bencardino and Laura Palmeri and Andrea Sartore-Bianchi and Angelo Vanzulli and Sara Cresta and Silvia Damian and Matteo Duca and Elena Ardini and Gang Li and Jason Christiansen and Karey Kowalski and Ann D Johnson and Rupal D Patel and David Z. Luo and Edna Chow-Maneval and Zachary Hornby and Pratik S. Multani and Alice Tsang Shaw and Filippo De Braud},
  journal={Cancer discovery},
  year={2017},
  volume={7 4},
  pages={400-409}
}
Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions, naïve to prior TKI treatment targeting the specific gene, and who were treated at… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 90 times over the past 90 days. VIEW TWEETS